Cargando...
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...
Gardado en:
| Publicado en: | Turk J Haematol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Galenos Publishing
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4451485/ https://ncbi.nlm.nih.gov/pubmed/26316485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2013.0265 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|